Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366580 | 1.00 | CETP (0.91) | CETPNR1I2 | |
| SCHEMBL10245315 | 0.95 | CETP (0.94) | CETPNR1I2 | |
| SCHEMBL15706605 | 0.95 | CETP (0.94) | CETPNR1I2 | |
| SCHEMBL17585956 | 0.95 | CETP (0.94) | CETPNR1I2 | |
| SCHEMBL17585942 | 0.95 | CETP (0.91) | CETPNR1I2 | |
| SCHEMBL15927667 | 0.95 | CETP (0.91) | CETPNR1I2 | |
| Anacetrapib SCHEMBL531448 | 0.95 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL22281463 | 0.95 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL18432840 | 0.95 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL29807658 | 0.95 | CETP (1.00) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486983-B2 | Self-emulsifying formulations of CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-8030359-B2 | Polymer formulations of CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7863307-B2 | Process for synthesizing a CETP inhibitor | MERCK SHARP & DOHME LLC | 2011-01-04 | — | — | US | disclosed |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090186926-A1 | Self-Emulsifying Formulations of CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186926-A1 | Self-Emulsifying Formulations of CETP Inhibitors | CETP, LIPA, LIPC | CETP 1/4885NR1I2 443/4885 |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | CETP, MTTP, CTDSP1 | CETP 1/4885NR1I2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.